Karachi: IBL Healthcare Limited has released its condensed interim financial information for the nine-month period ending March 31, 2025. The financial statements, prepared in compliance with the International Accounting Standard (IAS) 34 and the Companies Act, 2017, provide a detailed account of the company's financial performance.

The principal activities of IBL Healthcare Limited include the marketing, selling, and distribution of healthcare, consumer, and medical devices portfolios. For the period under review, the company reported revenue of PKR 3,145 million, which remained nearly consistent with the PKR 3,182 million recorded during the same period last year. The company achieved an improvement in gross profit margins, which rose to 31% from 26% reported in the annual report for the year ended June 30, 2024.

Operating expenses were reduced by 15% compared to the same period last year, attributed to disciplined cost control measures. Despite these cost savings, the profit after tax stood at 4%, a decline from 5% in the corresponding period of the previous year. The decrease in profit margin is attributed to higher tax incidence and the absence of exchange gains.

According to information available from the Pakistan Stock Exchange (PSX), IBL Healthcare Limited's financial performance reflects the company's efforts to sustain profitability amidst challenging conditions. The company's focus remains on operational excellence and strategic initiatives to drive long-term growth.

Looking forward, IBL Healthcare Limited is committed to delivering superior products and services. The company aims to create greater value for all stakeholders by adhering to ethical practices and ensuring alignment with core values and principles. The designated market category for the company's shares is the healthcare sector.